Mineralys Therapeutics, Inc. (MLYS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Mineralys Therapeutics, Inc. (MLYS) closed at USD 20.76 on 2026-10-14, a change of -49 % over the past year, with a market capitalization of USD 1.91B.

Mineralys Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Mineralys Therapeutics, Inc. key figures

Previous close

USD 20.76 (2026-10-14)

1-year change

-49 %

Market cap

USD 1.91B

Enterprise value

USD 1.35B

P/E ratio (trailing)

-5.13

P/E ratio (forward)

-8.66

EPS (trailing)

-4.22

EPS (forward)

-2.50

PEG ratio

n/a

Price to book

3.47

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.22

Employees

76

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Mineralys Therapeutics, Inc. and compare it with other stocks.